Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that cutaneous adverse reactions to bortezomib and lenalidomide are more frequent than reported, impacting patients' quality of life and may require dermatological consultation for proper management.

This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.

This report presents the Taiwanese Dermatological Association's 2016 consensus on defining and managing skin toxicities from EGFR-TKI treatments, providing comprehensive guidelines for clinicians in Taiwan.

This study found that in first-line treatment of metastatic breast cancer, pegylated liposomal doxorubicin (PLD) provided similar progression-free survival to doxorubicin with significantly less cardiotoxicity.

This article discusses the various skin side effects associated with targeted cancer therapies like tyrosine kinase inhibitors and EGF-R inhibitors but provides no new clinical findings.

This review examined the potential effects of Kampo medicine Hangeshashinto on oral mucositis, highlighting that several natural products in its composition may inhibit intracellular AGEs, reduce inflammation from extracellular AGEs, and suppress cytotoxicity in stomatitis.

This study observed that pediatric bone marrow transplantation patients frequently experience various dermatological issues; mucositis and xeroderma were the most common.

This case report describes two patients experiencing a bortezomib-induced skin eruption as multiple plaques on the trunk, with the lesions resolving spontaneously in about a week.

The authors concluded that pegylated liposomal doxorubicin may offer comparable efficacy to conventional doxorubicin with reduced toxicity in metastatic breast cancer treatment.

This review elaborates on the skin side effects of chemotherapy and emphasizes identifying and managing both common and life-threatening skin reactions, without presenting new clinical findings.

This article discusses the cutaneous side effects of various chemotherapeutic agents but reports no new clinical results; the authors emphasize the importance of dermatologists recognizing drug-induced skin reactions to better patient care.

In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.

This review describes the variety of mucocutaneous side effects caused by antineoplastic chemotherapy, with emphasis on skin, nails, and mucous membranes, while highlighting potential severity and the possibility of needing to adjust or interrupt treatment in rare cases; it presents no new clinical results.

This article reviews common skin eruptions in chemotherapy patients and discusses how recognizing these patterns can help avoid unnecessary changes to cancer treatment; it reports no new clinical results.

This study identified specific profiles and courses of adverse events associated with boron neutron capture therapy for head and neck cancer, suggesting differences based on the beam incidence site.

This review discusses the skin side effects associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for empirical management based on expert opinion.

This chapter reviews the structure, pharmacokinetics, and clinical applications of PEGylated liposomes and reports no new research findings.

In this study conducted at the Pediatric Hematology-Oncology Ward, 65% of hospitalized pediatric cancer patients developed dermatological lesions, predominantly alopecia and mucositis, possibly due to the administration of plant alkaloid chemotherapy, consistent with existing literature.

This study analyzed 19 clinical trials and found that dermatologic adverse events, such as rash, xerosis, and mucositis, frequently occur in pediatric patients receiving targeted anticancer therapies.

This review discusses the shift in toxicity profiles of cancer therapies from traditional chemotherapy to targeted agents, noting similar overall toxicities but with different side effects, and reports no new findings.

This review highlights that dermatologic side effects of cancer therapies, such as chemotherapy and immunotherapy, are increasingly complex, emphasizing the importance of preventive and management strategies to reduce skin toxicity and improve treatment adherence.

This review highlighted that targeted cancer therapies, while generally causing mild toxicities that can be managed, also pose risks of rare but serious side effects like pneumonitis and cardiotoxicities, emphasizing the need for vigilant monitoring and management to ensure patient safety.

In patients undergoing treatment with capecitabine for colon cancer and metastatic breast cancer, this study observed that hand-foot syndrome occurred more frequently than with intravenous 5-FU, but other side effects were less common.

This study found that patient-reported outcomes revealed the persistence of neuropathy, insomnia, and nail changes in breast cancer patients beyond chemotherapy, emphasizing the importance of monitoring long-term adverse events.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

This review discusses the side effects associated with ovarian cancer treatment and highlights the need for tools to assess, prevent, and manage these effects; it reports no clinical results.

This review highlights the potential of Sacituzumab Tirumotecan, an antibody-drug conjugate, in treating gynecologic cancers, with ongoing Phase III trials indicating a manageable safety profile and future results expected to shed light on its effectiveness in improving survival and response rates.

This review outlines the oral toxic effects of chemotherapy and stresses the need for evaluating dental health prior to treatment to mitigate these complications, but it reports no new clinical results.

This narrative review evaluates evidence that regional hypothermia can reduce oral, hair, eye, and nail complications from chemotherapy, but highlights the need for more research to address study limitations.

This review highlights the significant impact of cutaneous and oral mucosal adverse events on patients undergoing breast cancer treatment, emphasizing the need for early detection and comprehensive management to maintain treatment adherence and enhance patient care.